USE OF GALECTIN-3 FOR RISK ASSESSMENT AND DETECTION OF PREECLAMPSIA AND RELATED CONDITIONS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 26, 2013
app pub date -
Jan 7, 2013
filing date -
Jan 6, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Described herein are materials and methods for predicting and/or monitoring preeclampsia and related conditions, including eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, left ventricular dysfunction, and heart failure, in a pregnant or post-partum woman. More specifically, use of the endogenous protein galectin-3 in predicting and/or monitoring preeclampsia and related conditions in a pregnant or post-partum woman is described. Also described are methods of preventing and/or treating preeclampsia and related conditions by inhibiting galectin-3.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully